Seroepidemiologic Survey of Varicella-Zoster Virus in Korean Adults Using Glycoprotein Enzyme Immuno Assay and Fluorescent Antibody to Membrane Antigen Test

Kim, Yun Hwa; Hwang, Ji Young; Lee, Kyung Min; Choi, Jin Hee; Lee, Tae Yoon; Choi, Jong Soo; Park, Ho Sun

doi:10.5021/ad.2011.23.1.39

Cited by 7 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Choi et al (8) reported the seroprevalence in subjects < 1 yr of age to over 75 yr of age and the results were similar to our study. Another study was performed in subjects over 40 yr of age using fluorescent antibody to membrane antigen test (FAMA) and the results showed seropositivity of 98.6% in that age group (9). According to age groups, our results showed seroprevalence of 67.3% in subjects as early as 1-4 yr of age.…”

Section: Discussionmentioning

confidence: 99%

Seroepidemiology of Varicella-Zoster Virus in Korea

2013

View full text Add to dashboard Cite

This study was designed to assess the immune status of the Korean population against varicella-zoster virus (VZV) through a seroepidemiologic study. Residual blood samples were collected from diagnostic laboratories throughout Korea. Samples were collected in October 2009 to March 2010 from persons 0-79 yr of age and were tested by ELISA (Enzygnost®; Dade Behring, Schwalbach, Germany). Total seroprevalence in subjects 1-79 yr of age was 89.6%. Seroprevalence increased as age increased from 67.3% in subjects 1-4 yr of age to 94.2% in subjects 10-14 yr of age and in subjects over 20 yr of age seroprevalence ranged from 98.0% to 100%. In children under 1 yr of age, passive immunity waned after birth with none of the subjects having antibodies from 7 months of age and over. Among subjects 1-79 yr of age, susceptible subjects to VZV were mainly under 20 yr of age. These results provide information in understanding the dynamics of varicella disease in Korea, which is important in building up strategies for disease control.

show abstract

Section: Discussionmentioning

confidence: 99%

Seroepidemiology of Varicella-Zoster Virus in Korea

2013

View full text Add to dashboard Cite

show abstract

“…However, unfixed cells cannot be stored for a long time, therefore, some laboratories used glutaraldehyde for cell fixing 31-33. Besides fixation methods, cell lines, VZV strains, reference sera, and cutoff values are different between laboratories 3,20,24,30,31,33-35. Williams, et al3 used a wild type VZV Ellen strain, and recently the Oka vaccine strain has been used in some laboratories 3,30,33,35.…”

Section: Resultsmentioning

confidence: 99%

“…MGLu cells were cultured and infected with Varilrix™ (GSK, UK) as described previously 30. When 60-70% of the cells showed a cytopathic effect, cells were harvested and used as a FAMA antigen 30. The FAMA test was performed according to William's method with some modification 3,30.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of a Commercial Glycoprotein Enzyme-Linked Immunosorbent Assay for Measuring Vaccine Immunity to Varicella

et al. 2014

Self Cite

View full text Add to dashboard Cite

PurposeTo evaluate a recently marketed commercial glycoprotein enzyme-linked immunosorbent assay (gpEIA) kit, the VaccZyme™ VZV gpEIA, for measuring the immunity of varicella-vaccinated children.Materials and MethodsWe investigated the accuracy and reproducibility of the VaccZyme™ VZV gpEIA kit for the detection of antibodies to VZV. We also examined the sensitivity, specificity, and correlation between antibody titers calculated with gpEIA versus fluorescent antibody to membrane antigen (FAMA) by using sera of 349 children, ranging from 1 to 6 years old.ResultsVaccZyme™ VZV gpEIA gave precise and reproducible intra- and inter-assay results. FAMA and gpEIA titers showed a linear correlation (Pearson correlation coefficient=0.987). The sensitivity and specificity of the VaccZyme™ gpEIA was 31.4% and 100%, respectively, when the guidelines of the gpEIA (<100 mIU/mL) and FAMA 1:4 were adopted as cutoff values. However, the maximum sensitivity and specificity were 88.9% and 95.1%, respectively, with the highest correlation (κ=0.840), if the cutoff values were set with gpEIA at 49.7 mIU/mL and FAMA 1:16.ConclusionThese results demonstrate that the VaccZyme™ VZV gpEIA kit gave precise and reproducible data for measuring antibody titer after varicella vaccination. The results also showed that the antibody titer calculated with the VaccZyme™ gpEIA kit strongly correlated with the FAMA titer. However, cutoff values should be re-optimized for the evaluation of vaccine immunity.

show abstract

“…In recent years, researchers around the world have screened protective antigens of varicella zoster virus (VZV), exploring a series of antigen markers with various degrees of immune protective effects (1). Previous studies have demonstrated that the glycoprotein E (gE) antigen is one of the most promising candidate antigen markers (2,3). gE is one of the most important protective antigens in VZV, and since it is capable of inducing cellular and humoral immunity, gE is considered the most appropriate candidate antigen for a DNA vaccine (4).…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine

Wei

Gan

Ren

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. In the present study a eukaryotic expression vector of varicella zoster virus (VZV) glycoprotein E (gE) was constructed and enabled to express in COS7 cells. Furthermore, a specific immune response against the VZV gE eukaryotic expression plasmid was induced in BALB/c mice. The VZV gE gene was amplified using polymerase chain reaction (PCR) and cloned into a eukaryotic expression vector, pcDNA3.1. The recombinant vector was subsequently transfected into COS7 cells using a liposome transfection reagent. The recombinant protein was instantaneously expressed by the transfected cells, as detected by immunohistochemistry, and the recombinant pcDNA-VZV gE plasmid was subsequently used to immunize mice. Tissue expression levels were analyzed by reverse transcription-PCR. In addition, the levels of serum antibodies and spleen lymphocyte proliferation activity were investigated. The amplified target gene included the full-length gE gene (~2.7 kb), and the recombinant expression vector induced gE expression in COS7 cells. In addition, the expression plasmid induced sustained expression in vivo following immunization of mice. Furthermore, the plasmid was capable of inducing specific antibody production and effectively stimulating T cell proliferation. Effective humoral and cellular immunity was triggered in the mice immunized with the VZV gE eukaryotic expression vector. The results of the present study laid the foundation for future research into a VZV DNA vaccine.

show abstract

Seroepidemiologic Survey of Varicella-Zoster Virus in Korean Adults Using Glycoprotein Enzyme Immuno Assay and Fluorescent Antibody to Membrane Antigen Test

Abstract: Most (90.2%) Korean adults ≥40-years-of-age have a protective level of gpEIA antibody against varicella and 98.6% were FAMA seropositive. The GMT of gpEIA antibody was significantly increased with age, and was higher in adults with a history of HZ.

Cited by 7 publications

References 15 publications

Seroepidemiology of Varicella-Zoster Virus in Korea

Seroepidemiology of Varicella-Zoster Virus in Korea

Evaluation of a Commercial Glycoprotein Enzyme-Linked Immunosorbent Assay for Measuring Vaccine Immunity to Varicella

Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine

Contact Info

Product

Resources

About